Clinical Trial: A First-in-Human Single and Multiple Ascending Dose Study of MT-251

U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07423299) titled 'A First-in-Human Single and Multiple Ascending Dose Study of MT-251' on Feb. 13.

Brief Summary: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Doses of MT-251 in Healthy Participants

Study Start Date: Jan. 23

Study Type: INTERVENTIONAL

Condition: Healthy Volunteers

Intervention: DRUG: MT-251

MT-251

Recruitment Status: RECRUITING

Sponsor: Mirador Therapeutics, Inc.

Disclaimer: Curated by HT Syndication....